Anti-CD20 therapies for multiple sclerosis have come to dominate the therapeutic (and publishing) landscape. Thus far in 2026, six studies have compared the relative efficacy and safety of ocrelizumab and rituximab. Read More
Latest News
Highlights of EAN 2026 – Part 2
July 9, 2026The following are selected presentations from the 12th Congress of the European Academy of Neurology, held June 27-30, 2026 in Geneva, Switzerland
Ocrelizumab discontinuation
Role of fluid biomarkers in practice
Cyclophosphamide vs. siponimod in SPMS
Relapse during pregnancy in MOGAD, NMOSD
GLP-1 signalling in NMOSD
Read More
Highlights of EAN 2026 – Part 1
June 30, 2026The following are selected presentations from the 12th Congress of the European Academy of Neurology, held June 27-30, 2026 in Geneva, Switzerland
Are annual MRIs necessary?
Effect of HE DMTs on PIRA
Impact of ofatumumab on brain atrophy
Frexalimab long-term results
Increasing prevalence of NMOSD in Finland
Read More
CLINICAL CASES IN NEUROLOGY – A PERIMENOPAUSAL WOMAN WITH MIGRAINE AND HEAD TRAUMA
May 25, 2026Click here to watch Dr. Jiwon Oh discuss the case and your responses to the quick poll.
Ellen is a 48-year-old elementary teacher with a history of migraine dating back to her twenties. She is perimenopausal with hot flashes and fatigue, and a recent increase in migraine frequency to 5-6 headaches per month. Her family physician diagnosed depression two years ago and started Ellen on a trial of sertraline. Read More